Master Trial Index (All Years)

Chest

Dexmedetomidine showed a mortality trend (P=0.091, NS) with significant physiological improvements.

AJRCCM

Lung-protective ventilation in severe brain injury WORSENED mortality, ventilator dependency, and neuro outcome.

Intensive Care Med

The 1-hour sepsis bundle showed no clear in-hospital mortality benefit in this stepped-wedge ED trial.

BMJ

Cardiac output-guided hemodynamic therapy did not reduce postoperative infection in major GI surgery.

JAMA Netw Open

Iloprost showed no organ-dysfunction benefit even in biomarker-selected endotheliopathy septic shock.

JAMA

Acetaminophen no benefit overall; promising high-cell-free-hemoglobin subgroup warrants phase 3.

Nutr Metab (Lond)

Smaller single-center trial found early high protein reduced mortality — contradicts the larger PRECISe trial.

JAMA

Continuous beta-lactam infusion trended toward lower mortality (P=0.08) with significant clinical-cure benefit.

NEJM

Liberal transfusion trended better in TBI but didn't reach significance; pooled meta-analysis found no clear difference.

NEJM

Andexanet gave superior hemostasis in factor Xa-ICH but significantly increased thrombotic events.

JAMA

HFNO noninferior to NIV in 4 of 5 ARF groups, but WORSE in immunocompromised patients with hypoxemia.

JAMA

Thrombectomy for large infarct selected by noncontrast CT alone: no significant functional benefit, wide CI.

JAMA

Liberal transfusion significantly improved outcome in acute brain injury (62.6% vs 72.6% unfavorable, P=0.002).

NEJM

IO-first vs IV-first vascular access in OHCA: 30d survival unchanged (4.5% vs 5.1%).

Intensive Care Med

Conservative vs liberal oxygen on VA-ECMO; full quantitative results not accessible for this summary.

JAMA

EEG-guided anesthesia reduced EEG suppression time 66% but did NOT reduce postoperative delirium.

NEJM

7-day antibiotics noninferior to 14 days for bloodstream infections (90d mortality 14.5% vs 16.1%).

JAMA

Nonselective extracorporeal blood purification significantly reduced cardiac-surgery-associated AKI (28.4% vs 39.7%).

JAMA

Dedicated kidney action team improved implementation but did not reduce worsening AKI, dialysis, or death.

NEJM

Liberal transfusion did not clearly improve neurologic outcomes specifically in aneurysmal SAH.

NEJM

IV amino acids reduced AKI occurrence, but benefit limited to mild stages with no RRT/mortality effect.

JAMA

qSOFA-based electronic sepsis screening significantly reduced 90-day in-hospital mortality (NNS~206).

Circulation

Mechanical thrombectomy beat catheter-directed thrombolysis on composite (win ratio 5.01), but hard outcomes equivalent.

Intensive Care Med

Early spontaneous ventilation gave identical hospital mortality vs conventional volume assist-control.

JAMA

Tenecteplase noninferior to alteplase for standard-window acute ischemic stroke.

Lancet Respir Med

Individualized short-course antibiotics for VAP noninferior, cut antibiotic side effects from 38% to 8%.

Lancet Respir Med

Neither haloperidol nor ziprasidone for ICU delirium showed long-term cognitive, functional, or psychological benefit.

JAMA

Neither screening frequency nor SBT technique alone mattered, but combining them unexpectedly slowed extubation.

JAMA

Automated fever prevention reduced fever burden but did NOT improve 90-day functional outcomes.

NEJM Evidence

Early in-bed cycle ergometry did not improve physical function after ICU discharge.

JAMA

Early restrictive vs liberal oxygen in trauma patients: death/major respiratory complications identical.

NEJM

Danish trial confirms no significant difference between IO-first and IV-first access in OHCA.

Intensive Care Med

Landiolol significantly controlled persistent tachycardia in septic shock (P=0.013) without added vasopressor need.

Chest

Adding metagenomic sequencing to conventional testing significantly sped clinical improvement in severe CAP.

JAMA Netw Open

Investigational 4-factor PCC matched a licensed comparator for VKA reversal before urgent surgery; now FDA-approved.

NEJM

First randomized trial to meet its primary endpoint for surgical ICH evacuation, after decades of neutral trials.

JAMA

PCT-guided (not CRP-guided) antibiotic-stopping protocol safely reduced duration by ~0.9 days.

Intensive Care Med

Ilofotase alfa phase 3 did not improve 28d survival in sepsis-associated AKI, despite promising phase 2 signal.

NEJM

IV pantoprazole significantly reduced GI bleeding (1.0% vs 3.5%) with no mortality penalty.

Hepatology

Tranexamic acid significantly reduced 5-day treatment failure (6.3% vs 13.3%) in cirrhosis-associated UGIB.

Lancet

High-protein enteral feeding resulted in significantly WORSE quality of life, no functional benefit.

Intensive Care Med

Low-dose clonidine gave ~100 more minutes of sleep in postoperative HDU patients, no serious adverse events.

NEJM

First mechanical circulatory support to show a mortality benefit in STEMI-cardiogenic shock (45.8% vs 58.5%).

NEJM

15h/day long-term oxygen therapy as effective as 24h/day; largest trial of its kind.

Circulation

Mechanical thrombectomy improved RV/LV ratio in intermediate-high-risk PE; first RCT of its kind since 2013.

NEJM

Ketamine vs etomidate for RSI: no mortality difference, but ketamine caused more CV collapse.

Lancet

Biomarker-guided KDIGO prevention bundle significantly reduced postoperative AKI (14.4% vs 22.3%).

JAMA

Cryopreserved platelets failed noninferiority vs liquid-stored (bleeding ratio 1.13), more costly.

JAMA

Adjunctive IA alteplase after successful thrombectomy improved outcome AND reduced mortality.

Crit Care

Adjunctive terlipressin improved hemodynamics at 6h (P=0.039) but effect didn't persist; mortality unchanged.